- Home
- Automated
- List of product information
- HIBERIX VACCINE 10 MCG/0.5 ML [SIN09859P]
HIBERIX VACCINE 10 MCG/0.5 ML [SIN09859P]
Active ingredients: HIBERIX VACCINE 10 MCG/0.5 ML
Last updated 26 October 2025
On this page
Product Info
HIBERIX VACCINE 10 MCG/0.5 ML
[SIN09859P]
Product information
Active Ingredient and Strength | PURIFIED CAPSULAR POLYSACCHARIDE OF HIB - 10 MCG/0.5 ML |
Dosage Form | INJECTION, POWDER, FOR SOLUTION |
Manufacturer and Country | GLAXOSMITHKLINE BIOLOGICALS - FRANCE |
Registration Number | SIN09859P |
Licence Holder | GLAXOSMITHKLINE PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | J07AG01 |
Indications
Hiberix is indicated for active immunisation of all infants from the age of 6 weeks against disease caused by Hib.
Hiberix does not protect against disease due to other types of H. influenzae nor against meningitis caused by other organisms.
Dosage and Administration
Posology
The primary vaccination schedule consists of three doses in the first 6 months of life and can start from the age of 6 weeks.
To ensure a long term protection, a booster dose is recommended in the second year of life.
Infants between the ages of 6 and 12 months previously unvaccinated should receive 2 injections, given with an interval of one month, followed by a booster in the second year of life. Previously unvaccinated children aged 1–5 years should be given one dose of vaccine.
As vaccination schemes vary from country to country, the schedule for each country may be used in accordance with the different national recommendations.
Method of Administration
The reconstituted vaccine is for intramuscular injection. However, it is good clinical practice that in patients with thrombocytopenia or bleeding disorders the vaccine should be administered subcutaneously.
Contraindications
Hiberix should not be administered to subjects with known hypersensitivity to any component of the vaccine, or to subjects having shown signs of hypersensitivity after previous administration of Hib vaccines.